Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO)

被引：0
|
作者：
Chen, Inna Markovna
Johansen, Julia S.
Theile, Susann
Madsen, Kasper
Dajani, Olav
Lorentzen, Torben
Zimmers, Teresa
Nielsen, Dorte
机构：
[1] Copenhagen Univ Hosp Herlev & Gentofte, Herlev, Denmark
[2] Oslo Univ Hosp, Oslo, Norway
[3] Indiana Univ Sch Med, Indianapolis, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4147
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Borazanci, Erkut
    Schroeder, Katy
    Jameson, Gayle S.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Lei Yang
    Jing Su
    Wenbo Wang
    Fuxiang Zhou
    World Journal of Surgical Oncology, 21
  • [43] Efficacy and safety of gemcitabine/nab-paclitaxel combined with anlotinib and PD-1 inhibitors as a first-line treatment for advanced pancreatic cancer
    Liu, Haonan
    Pan, Di
    Yao, Zhiyuan
    Wang, Hongmei
    Li, Yuqi
    Qin, Xiaobing
    Qu, Pengfei
    Tang, Juanjuan
    Han, Zhengxiang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 139
  • [44] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Yang, Lei
    Su, Jing
    Wang, Wenbo
    Zhou, Fuxiang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [45] NAB-PACLITAXEL IN THE TREATMENT OF ADVANCED PANCREATIC CANCER REFRACTORY TO GEMCITABINE - FINAL RESULTS OF A PHASE 2 TRIAL
    Lopes, G. de Lima
    Hosein, P.
    Gomez, C.
    Pastorini, V.
    Macintyre, J.
    Easey, M.
    Reis, I.
    Merchan, J.
    Bejarano, P.
    Rocha-Lima, C.
    EJC SUPPLEMENTS, 2011, 9 (01): : 1 - 1
  • [46] Toripalimab combined with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a phase Ib/II clinical study.
    Cheng, Ke
    Lv, Wanrui
    Li, Xiaofen
    Chang, Chen
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16244 - E16244
  • [47] Third -line re -treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel
    Das, A.
    Dean, A.
    McNulty, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
    Tempero, M.
    Oh, D.
    Macarulla, T.
    Reni, M.
    Van Cutsem, E.
    Hendifar, A.
    Waldschmidt, D.
    Starling, N.
    Bachet, J.
    Chang, H.
    Maurel, J.
    Lonardi, S.
    Coussens, L.
    Fong, L.
    Tsao, L.
    Cole, G., Jr.
    James, D.
    Tebernero, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 126 - 126
  • [49] Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study
    Williet, Nicolas
    Saint, Angelique
    Pointet, Anne-Laure
    Tougeron, David
    Pernot, Simon
    Pozet, Astrid
    Bechade, Dominique
    Trouilloud, Isabelle
    Lourenco, Nelson
    Hautefeuille, Vincent
    Locher, Christophe
    Desrame, Jerome
    Artru, Pascal
    Bidault, Anne Thirot
    Le Roy, Bertrand
    Pezet, Denis
    Phelip, Jean-Marc
    Taieb, Julien
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [50] Maintenance treatment with gemcitabine after gemcitabine plus Nab-paclitaxel in advanced pancreatic cancer
    Kodama, Tomoko
    Nakazawa, Junichi
    Kawahira, Masahiro
    Ymasuji, Akihiro
    Iwashita, Yuji
    Hori, Takeshi
    Kawahira, Machiko
    Arima, Shiho
    Tubouchi, Hirohito
    Ido, Akio
    ANNALS OF ONCOLOGY, 2022, 33 : S484 - S484
12345